Supriya Lifescience Ltd

NSE
SUPRIYA •
BUY

1W Return

-%

1M Return

-%

6M Return

-%

1Y Return

-%

3Y Return

-%

Start SIP in Supriya Lifescience Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
103.38% Gain from 52W Low
22.6
TTM PE Ratio
Below industry Median
23.1
Price to Book Ratio
Above industry Median
4
Dividend yield 1yr %
Low in industry
0.2
TTM PEG Ratio
PEG TTM is less than 1
1
RSI
RSI is mid-range
54.2
MFI
MFI is mid-range
60.2

Supriya Lifescience Ltd shareholding Pattern

Promoter
68.3%
Foreign Institutions
4.6%
Domestic Institutions
5.4%
Public
21.8%

Supriya Lifescience Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
11
Bearish Moving Averages
5
5Day EMA
347.90
10Day EMA
348.80
12Day EMA
348.10
20Day EMA
342.90
26Day EMA
338.50
50Day EMA
323.60
100Day EMA
303.70
200Day EMA
287.50
Delivery & Volume
Resistance & Support
346.22
Pivot
Resistance
First Resistance
349.78
Second Resistance
353.52
Third Resistance
357.08
Support
First Support
342.48
Second support
338.92
Third Support
335.18
Relative Strength Index
54.20
Money Flow Index
60.18
MACD
9.56
MACD Signal
12
Average True Range
17.23
Average Directional Index
39.29
Rate of Change (21)
14.09
Rate of Change (125)
23.52

Supriya Lifescience Ltd Company background

Founded in: 2008
Managing director: Satish Waman Wagh
The company was incorporated as Supriya Lifescience Limited on 26 March 2008 upon the conversion of M/s Supriya Chemicals,a partnership firm, into a public limited company.The company commenced operations on 01 April 2008.The company is engaged in manufacturing and export of active pharmaceutical ingredients(APIs).The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients,with a focus on research and development. As of 31 March 2021,the company have niche product offerings of 39 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, antiasthmatic and antiallergic.The company have consistently been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 4555% and 6570%, respectively,of the API exports from India, between Fiscal 2017 and 2020.The company is among the largest exporters of Salbutamol Sulphate from India in Fiscal 2020 in terms of volume.The companys products are approved by various international regulatory authorities such as USFDA, EUGMP, EDQM, SFDA NMPA, ANVISA, KFDA, PMDA, TGA and Taiwan FDA. As of 31 March 2021, the company have filed 11 active DMFs with USFDA and seven active CEPs with EDQM, for API products in therapeutic areas such as antihistamine, analgesic, anaesthetic, vitamin, antiasthmatic and antiallergic.The companys business operations are supported by a modern manufacturing facility located in Parshuram Lote, Maharashtra. The manufacturing facility is spread across 23,806 sq.mts, having reactor capacity of 332 KL per day.The company presently operate five cleanrooms and are setting up two new clean rooms that are expected to be commercialised in the first quarter of Fiscal 2022. The new clean rooms will add manufacturing capacity of 215 KL per day.On 31 March 2012,the company has issued and allotted 3002400 equity shares of Rs 10 each as bonus shares to the shareholders in the ratio of 12:1.On 31 March 2013,the company has issued and allotted 1626302 equity shares of Rs 10 each as bonus shares to the shareholders in the ratio of 1:2.On 01 October 2015,the company has issued and allotted 9757804 equity shares of Rs 10 each as bonus shares to the shareholders in the ratio of 2:1On 26 December 2020,the company has subdivided its face value of equity shares from Rs 10 each to Rs 2 each.During the month of December 2021,the company came out with an Rs 700crore public issue which comprised of a fresh issue of Rs 200 crore and an offer for sale(OFS) of Rs 500 crore by the promoter Satish Waman Wagh.The IPO shares were allotted at the price of Rs 274 per share including a premium of Rs 272 per share.The allotted shares were listed on the BSE Ltd and National Stock Exchange of India Ltd(NSE) on 28 December 2021.
Read More

Supriya Lifescience Ltd FAQs

Supriya Lifescience Ltd shares are currently priced at 346.05 on NSE and 346.35 on BSE as of 2/29/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Supriya Lifescience Ltd [SUPRIYA] share was 74.06. The Supriya Lifescience Ltd [SUPRIYA] share hit a 1-year low of Rs. 170.15 and a 1-year high of Rs. 394.

The market cap of Supriya Lifescience Ltd is Rs. 2785.11 Cr. as of 2/29/2024 12:00:00 AM.

The PE ratios of Supriya Lifescience Ltd is 23.15 as of 2/29/2024 12:00:00 AM.

The PB ratios of Supriya Lifescience Ltd is 3.7 as of 2/29/2024 12:00:00 AM

The Mutual Fund Shareholding was 0.04% at the end of 2/29/2024 12:00:00 AM.

You can easily buy Supriya Lifescience Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
or Resume your Application
+91 -

personImage